Harvesting the low-hanging fruit: kinase inhibitors for therapy of advanced medullary and nonmedullary thyroid cancer

J Clin Endocrinol Metab. 2010 Jun;95(6):2621-4. doi: 10.1210/jc.2010-0800.
No abstract available

Publication types

  • Editorial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Adenocarcinoma, Follicular / drug therapy
  • Adenocarcinoma, Follicular / genetics
  • Adenocarcinoma, Follicular / pathology
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Benzenesulfonates / therapeutic use
  • Biomarkers, Tumor
  • Carcinoma, Medullary / drug therapy*
  • Carcinoma, Medullary / genetics
  • Carcinoma, Medullary / pathology
  • Carcinoma, Papillary / drug therapy
  • Carcinoma, Papillary / genetics
  • Carcinoma, Papillary / pathology
  • Humans
  • Indoles / adverse effects
  • Indoles / therapeutic use
  • Neoplasm Metastasis / prevention & control
  • Niacinamide / analogs & derivatives
  • Phenylurea Compounds
  • Protein Kinase Inhibitors / adverse effects
  • Protein Kinase Inhibitors / therapeutic use*
  • Pyridines / therapeutic use
  • Pyrroles / adverse effects
  • Pyrroles / therapeutic use
  • Sorafenib
  • Sunitinib
  • Thyroid Neoplasms / drug therapy*
  • Thyroid Neoplasms / genetics
  • Thyroid Neoplasms / pathology

Substances

  • Antineoplastic Agents
  • Benzenesulfonates
  • Biomarkers, Tumor
  • Indoles
  • Phenylurea Compounds
  • Protein Kinase Inhibitors
  • Pyridines
  • Pyrroles
  • Niacinamide
  • Sorafenib
  • Sunitinib